Current treatment of insulin resistance in type 2 diabetes mellitus

International Journal of Clinical Practice, Supplement

Volumn , Issue 113, 2000, Pages 54-62

  Tan, M H ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CARBOHYDRATE METABOLISM; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 33749220827     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. The triumvirate: b-cell, muscle and liver: A collusion responsible for NIDDM
2. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25 year follow-up study
3. Glucose: A continuous risk factor for cardiovascular disease
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Intensive blood glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: A randomized prospective 6-year study
7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
8. Pharmacologic therapy for type 2 diabetes mellitus
9. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes
10. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
11. Differential expression of peroxisome proliferator-activated receptors (PPAR): Tissue distribution of PPAR α, and γ in the adult rat
12. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
13. Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
14. Consensus development conference on insulin resistance
15. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
16. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus
17. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects
18. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM
19. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes
20. Decreased expression of glucose transporter in muscle from insulin-resistant patients
21. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity
22. Regulation of glucose transport by pioglitazone in cultured muscle cells
23. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
24. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone
25. Effect of pioglitazone on glucose tolerance and insulin sensitivity in diet-controlled type 2 diabetic subjects
26. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
27. Mechanism of free fatty acid-induced insulin resistance in humans
28. Dose finding study of AD-4833 in patients with NIDDM on diet therapy alone
29. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signalling in human muscle
30. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
31. Pioglitazone time-dependently reduces tumour necrosis factor-a level in muscle and improves metabolic abnormalities in Wistar fatty rats
32. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAγ mice
33. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
34. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin
35. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression
36. Acute effects of pioglitazone on glucose metabolism in perfused rat liver
37. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells
38. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
39. Antidiabetic agent pioglitazone increases insulin receptors on 3T3-L1 adipocytes
40. Pioglitazone is effective in the treatment of patients with type 2 diabetes
41. Effect of pioglitazone on blood glucose following an oral glucose challenge
42. Effect of pioglitazone on glucose metabolism in sulfonylurea-treated patients with type 2 diabetes
43. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
44. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
45. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
46. The HbA(1c) and blood glucose response to pioglitazone in combination with another antidiabetic agent in patients with type 2 diabetes
47. Pioglitazone reduces insulin resistance and improves beta cell function in type 2 diabetes patients receiving long term sulfonylurea therapy
48. The long-term effect of pioglitazone as monotherapy or combination therapy on glucose control in patients with type 2 diabetes
49. The long-term effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
50. Dyslipidaemias and coagulation defects of insulin resistance
51. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
52. Adverse events with pioglitazone HCl
53. The relationship of HbAlc and weight in the treatment of patients with type 2 diabetes
54. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)
55. Long-term echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone
56. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials
57. Effect of food on the pharmacokinetics of pioglitazone
58. Pioglitazone has low potential for drug interactions
59. Pharmacokinetics of pioglitazone in patients with renal impairment